The DOCK9 antibody is a research tool targeting Dedicator of Cytokinesis 9 (DOCK9), a member of the DOCK protein family involved in regulating intracellular signaling and cytoskeletal dynamics. DOCK9. also known as Zizimin2. belongs to the DOCK-D subfamily and functions as a guanine nucleotide exchange factor (GEF) specifically activating Cdc42. a Rho GTPase critical for cell polarity, membrane trafficking, and actin reorganization. Its expression is prominent in the brain, immune cells, and certain cancer types, linking it to neurological development, immune responses, and oncogenic processes. Antibodies against DOCK9 are commonly used to study its spatial-temporal expression, subcellular localization (e.g., membrane-associated signaling complexes), and interactions with downstream effectors. These antibodies are validated for techniques like Western blotting, immunofluorescence, and immunohistochemistry. Research applications focus on elucidating DOCK9's role in diseases, including neurodevelopmental disorders, immune dysregulation, and cancer metastasis, where aberrant Cdc42 signaling is implicated. Commercial DOCK9 antibodies are typically raised in rabbits or mice, with specificity confirmed through knockout controls or siRNA-based validation. Ongoing studies aim to clarify its tissue-specific regulatory mechanisms and therapeutic potential as a signaling node.